Bagman's charts, watchlists, scans and etc.

[The Profit Taker]

Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has launched the new web site for product purchasing of the Oxyview Nasal Cannula.

The Oxyview Nasal Cannula is available in various models for adult, pediatric and infant. Each age group can purchase the 0-6 liter/minute or the new "low flow" 0-3 liter/minute Oxyview Nasal Cannula. Included are discounts for purchasing the 10-Pack, 50-Pack or 100-Pack containers.

Chronic obstructive pulmonary disease (COPD) is conventionally thought of as a disease of adult smokers, related to airway inflammation and structural airway changes (remodeling). However, there is important epidemiological evidence, from a series of studies with overlapping age groups from birth to late middle age that early life events, including antenatal influences on lung growth, program the child to be at increased risk for future COPD.

"Initially the company had focused on the adult COPD market. Now the new low flow Oxyview Nasal Cannula opens doors to the pediatric and infant market for COPD patients. Although the Oxyview marketing campaign does not commence until September through December-2009, Ingen has banked more Oxyview revenue sales during our first quarter than any previous quarter simply through word-of-mouth. These results will be reported at the end of our first quarter on August 31, 2009," stated Thomas J. Neavitt, Chief Financial Officer.

http://www.ingen-tech.com/ovaiopurch.php

http://www.ncbi.nlm.nih.gov/pubmed/18259975

http://www.informaworld.com/smpp/content~content=a790482737~db=all~order=page

About Ingen:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Ingen Technologies, Inc.

CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
[e-mail]
www.INGEN-TECH.COM